Xeris Biopharma Holdings, Inc. XERS R2KR3KPHARMA
Company Overview
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Why Investors Should Care
Revenue has grown at a 95.1% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $291.85M (+43.7% YoY); net profit $554.00K.
- Trailing 12 Months Year-on-year growth — revenue +28.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 95.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 95.07% |
| 1 Year: | 28.70% |
Stock Price Performance
| 1 Year: | +17.17% |
| 6 Months: | +46.82% |
| 3 Months: | +38.03% |
| 1 Month: | +15.90% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)52.53 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 95.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XERS Xeris Biopharma Holdings, Inc. R2KR3KPHARMA | 8.53 | -85.30 | $1.56B | 0.00% | 9.09% | 4.05% | 95.07% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 9.40M | 8.05M | 8.91M | 11.06M | 22.07M | 25.31M | 29.73M | 33.20M | 38.01M | 48.32M | 40.64M | 48.06M | 54.27M | - | 60.12M | 71.54M | 74.38M | 85.81M | 83.13M | 92.10M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.73M | 11.90M | 11.00M | 10.95M | 10.57M | - |
| Gross Profit | - | - | 6.62M | - | - | 7.84M | - | - | - | - | - | - | - | - | - | - | 51.39M | 59.64M | 63.38M | 74.86M | 72.55M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.48M | 55.16M | 56.65M | 58.09M | 64.64M | - |
| Operating Income | - | - | -13.74M | -16.74M | -25.79M | -24.36M | -29.07M | -18.92M | -18.78M | -13.28M | -15.98M | -4.91M | -14.24M | -8.19M | -12.89M | - | -3.09M | 4.48M | 6.73M | 16.77M | 7.92M | 5.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.23M | 8.59M | 11.08M | 21.43M | 12.33M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.30M | 7.36M | 7.27M | 7.15M | 6.88M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Net Income | -29.18M | -24.10M | -16.00M | -18.41M | -27.52M | -26.01M | -33.71M | -26.18M | -21.83M | -16.83M | -19.84M | -12.19M | -18.98M | -15.01M | -15.74M | - | -9.22M | -1.93M | 621.00K | 11.08M | 2.23M | -31.10M |
| Diluted EPS | - | - | - | -0.30 | -0.41 | -0.39 | -0.25 | -0.19 | -0.16 | -0.12 | -0.14 | -0.09 | -0.14 | -0.10 | -0.11 | - | -0.06 | -0.01 | 0.00 | 0.06 | 0.01 | -0.18 |
| R&D Expense | - | - | 3.88M | 4.03M | 5.38M | 5.66M | 6.25M | 3.72M | 6.04M | 4.84M | 6.09M | 5.03M | 7.82M | 5.76M | 5.89M | - | 7.75M | 8.05M | 7.48M | - | 8.78M | 10.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 20.16M | - | 110.25M | 163.91M | 203.07M | 291.85M |
| Cost of Revenue | - | - | 22.63M | 28.64M | 36.83M | 42.57M |
| Gross Profit | - | - | 87.61M | 135.27M | 166.24M | 249.28M |
| Operating Expenses | - | - | 169.55M | 179.28M | 199.88M | 224.38M |
| Operating Income | -83.55M | - | -81.94M | -44.01M | -33.65M | 24.90M |
| EBITDA | - | - | -69.31M | -23.73M | -13.99M | 42.33M |
| Interest Expense | - | - | 14.10M | 26.61M | 30.48M | 29.08M |
| Pretax Income | - | - | -96.08M | -63.50M | -57.10M | 554.00K |
| Tax Provision | - | - | -1.42M | -1.25M | -2.27M | 0 |
| Net Income | -91.14M | - | -94.66M | -62.26M | -54.84M | 554.00K |
| Diluted EPS | - | - | -0.70 | -0.45 | -0.37 | 0.00 |
| R&D Expense | 20.92M | 25.16M | 20.97M | 22.34M | 25.56M | 31.16M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 159.15M | - | 344.52M | 322.60M | 323.06M | 383.53M |
| Current Assets | - | - | - | 186.82M | 156.26M | 167.66M | 240.31M |
| Cash & Equivalents | 19.52M | 37.60M | - | 121.97M | 67.45M | 71.62M | 111.04M |
| Inventory | - | - | - | 24.73M | 38.84M | 48.17M | 68.67M |
| Receivables | - | - | - | 30.83M | 39.20M | 40.41M | 51.05M |
| Total Liabilities | - | 125.39M | - | 299.33M | 329.38M | 352.68M | 369.84M |
| Current Liabilities | - | 28.21M | - | 73.62M | 95.19M | 100.44M | 109.57M |
| Long Term Debt | - | 87.02M | - | 187.07M | 190.93M | 217.01M | 220.34M |
| Total Debt | - | - | - | 198.06M | 229.19M | 271.45M | 258.10M |
| Total Equity | 14.44M | 33.76M | - | 45.19M | -6.78M | -29.61M | 13.69M |
| Shares Outstanding | - | - | - | 136.27M | 138.13M | 149.43M | 166.22M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -80.56M | - | -102.89M | -47.02M | -36.98M | 28.63M |
| Investing Cash Flow | -27.41M | - | 34.46M | -6.00M | 4.88M | -696.00K |
| Financing Cash Flow | 126.06M | - | 127.47M | -1.61M | 36.17M | 11.39M |
| Capital Expenditure | -377.00K | - | -524.00K | -2.26M | -868.00K | -696.00K |
| Free Cash Flow | -80.94M | - | -103.42M | -49.29M | -37.85M | 27.93M |
| Net Change in Cash | - | - | 59.04M | -54.64M | 4.07M | 39.32M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 79.5% | 82.5% | 81.9% | 85.4% |
| Operating Margin % | -414.5% | - | -74.3% | -26.8% | -16.6% | 8.5% |
| Net Margin % | -452.2% | - | -85.9% | -38.0% | -27.0% | 0.2% |
| ROE % | -270.0% | - | -209.5% | 917.9% | 185.2% | 4.0% |
| ROCE % | -63.8% | - | -30.2% | -19.4% | -15.1% | 9.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.97% | 14.53M | $123.18M |
| 2 | Shaw D.E. & Co., Inc. | 4.28% | 7.80M | $66.18M |
| 3 | Vanguard Capital Management LLC | 4.03% | 7.34M | $62.25M |
| 4 | State Street Corporation | 2.64% | 4.82M | $40.89M |
| 5 | Geode Capital Management, LLC | 2.59% | 4.72M | $40.01M |
| 6 | Nuveen, LLC | 2.41% | 4.39M | $37.19M |
| 7 | Rosalind Advisors, Inc. | 1.60% | 2.91M | $24.67M |
| 8 | Qube Research & Technologies Ltd | 1.59% | 2.89M | $24.54M |
| 9 | Vanguard Portfolio Management LLC | 1.44% | 2.63M | $22.27M |
| 10 | Wellington Management Group, LLP | 1.30% | 2.37M | $20.06M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XERS
Xeris (XERS) Q2 2026 Earnings Call Transcript
Recorlev revenue surged 81% year-over-year, driving tightened full-year guidance to $385M–$390M.
Xeris Biopharma Holdings Inc (XERS) (Q2 2026) Earnings Call Highlights: Record Revenue and ...
Xeris Biopharma Holdings Inc (XERS) posts a 29% revenue surge to $92.1 million, driven by RECORLEV's 81% growth, and lifts full-year 2026 outlook.
Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics
The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.…
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.…
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
CHICAGO, July 03, 2026--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants.
Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list. TheFly reported on June 11 that XERS announced that…
XERS — Frequently Asked Questions
What is the current share price of Xeris Biopharma Holdings, Inc. (XERS)?
As of 2026-09-07 16:24 PDT, Xeris Biopharma Holdings, Inc. (XERS) trades at $8.53 on NasdaqGS. Its 52-week range is $5.29 to $9.90.
What is the market capitalisation of XERS?
Xeris Biopharma Holdings, Inc. (XERS) has a market capitalisation of $1.56B on NasdaqGS.
What is the P/E ratio of XERS?
XERS trades at a trailing price-to-earnings (P/E) ratio of -85.30. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 96.71.
What is the return on equity (ROE) of XERS?
XERS has a return on equity (ROE) of 4.05%. Its return on capital employed (ROCE) is 9.09%.
Is XERS a good stock to buy?
This page provides a data-driven analysis of Xeris Biopharma Holdings, Inc. (XERS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.